Meeting Summary
The meeting discussed the current understanding of the role of immunoglobulin E (IgE) in asthma, and anti-IgE strategies in the treatment of severe asthma. Prof Gary Anderson provided an overview of the integral role of IgE in the inflammatory pathways involved in the pathogenesis of severe asthma and the development of omalizumab (Xolair®), an anti-IgE therapy. Prof William Busse presented some of the clinical findings on the use of omalizumab for virus-provoked asthma. Prof Jan Lötvall discussed how phenotyping could improve the development of patient-targeted treatment strategies in asthma. Finally, Prof David Price discussed how changes to the clinical management of patients with severe asthma could improve patient outcomes.
Please view the full content in the pdf above.






